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A postoperative troponin leak following non-
cardiac surgery is independently associated with 
30-day mortality.[1] Importantly, even what was 
previously considered an insignificant troponin leak 
(4th-generation troponin T >0.02 ng/ml) has been 
independently associated with 30-day mortality (odds ratio (OR) 
2.41; 95% confidence interval (CI) 1.33 - 3.77) in unselected patients 
aged ≥45 years who underwent non-cardiac surgery.[1] Over 40% 
of the population-attributable risk for 30-day mortality could be 
explained by the postoperative troponin leak.[1]
If generalisable, these data have wide-ranging public health 
implications. Firstly, of unselected patients aged ≥45 years undergoing 
non-cardiac surgery, over 11% are expected to have a prognostically 
important postoperative troponin leak.[1] Considering that over 
200 million surgical procedures on adults are performed annually 
worldwide,[2] and potentially half of these patients are ≥45 years of 
age, it is expected that more than 5 million people will suffer a major 
perioperative cardiovascular event (i.e. cardiovascular mortality or 
myocardial infarction) within 30 days of surgery,[1] and over 10 million 
will have a postoperative troponin leak of prognostic importance.[1] 
Should routine postoperative troponin surveillance be considered 
in this group of patients? Approximately a third of patients who 
have a postoperative troponin leak have a documented perioperative 
myocardial infarction.[3] Targeting all patients with a troponin leak 
after non-cardiac surgery, since it indicates a myocardial injury, 
may be justified, as 30-day and intermediate-term mortality is 
significantly increased even in patients who do not fulfil study 
criteria for a perioperative myocardial infarction.[1,4,5]
Unfortunately there is no prospective randomised evidence 
of the utility of therapy for improving cardiovascular outcomes 
following a perioperative myocardial infarction. There are, however, 
good observational cohort data from a primary preventive trial 
of perioperative myocardial infarction showing that statins and 
aspirin given at the time of perioperative myocardial infarction were 
independently associated with decreased 30-day mortality, with 
adjusted ORs of 0.54 (95% CI 0.29 - 0.99) and 0.26 (95% CI 0.13 - 
0.54), respectively.[6] Whether statin and aspirin therapy may also 
decrease mortality in patients who sustain a postoperative troponin 
leak secondary to myocardial ischaemia (which is now known 
as myocardial injury after non-cardiac surgery (MINS)), without 
fulfilling the Universal Definition of Myocardial Infarction,[7,8] is 
currently unknown.
Consideration of the economics of routine postoperative troponin 
surveillance is therefore warranted, as it is possible that the simple 
and inexpensive introduction of statin and aspirin therapy in patients 
who have a postoperative myocardial infarction may have a public 
health benefit, and should this benefit extend to MINS, it could be 
profound.
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Background. A postoperative troponin leak that was previously considered clinically insignificant has been independently associated with 
30-day mortality in unselected surgical patients ≥45 years of age following non-cardiac surgery.
Objectives. To determine whether routine troponin surveillance following non-cardiac surgery and initiation of aspirin and statin therapy 
in troponin-positive patients is cost-effective.
Methods. Pharmacoeconomic analysis to determine the cost-effectiveness of routine postoperative surveillance for patients aged ≥45 
years undergoing non-cardiac surgery. We compared the total expected cost of hospital care of patients who received routine troponin 
surveillance and subsequent introduction of statin and aspirin therapy for 30 days in troponin-positive patients with the cost of hospital 
care of patients who did not receive troponin surveillance. We estimated a 25% relative risk reduction following statin and aspirin therapy 
for postoperative vascular mortality and non-fatal myocardial infarction.
Results. Routine troponin surveillance with initiation of aspirin and statin therapy was cost-effective, with an incremental cost 
of –R16 724 per event avoided.
Conclusion. Routine postoperative troponin surveillance in non-cardiac surgical patients ≥45 years of age requiring a postoperative night 
in hospital is potentially cost-effective.
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The aim of this study was to determine whether routine troponin 
screening is cost-effective if a 25% relative risk reduction (RRR) 
in postoperative myocardial infarction and vascular mortality is 
achieved.
Methods
This pharmacoeconomic analysis determined the cost-effectiveness 
of routine postoperative surveillance for patients aged ≥45 years 
undergoing non-cardiac surgery.[1] It compared the total expected cost 
of hospital care of patients receiving routine troponin surveillance and 
subsequent introduction of statin and aspirin therapy for 30 days in 
troponin-positive patients with the cost of hospital care in patients who 
have not received troponin surveillance. We expected at least a 25% 
RRR in major cardiovascular complications (postoperative myocardial 
infarction and vascular death) at 30 days postoperatively should patients 
receive statin and aspirin therapy following a troponin leak. Based on 
the PeriOperative ISchemic Evaluation (POISE), trial we believed this 
to be a conservative estimate.[6] Using either the upper CIs (smallest 
treatment effect) or the point estimates (expected treatment effect) of the 
cardiovascular protection associated with statin and aspirin in patients 
who had an infarction, one would expect an RRR for 30-day mortality of 
0.53 (0.99 for statins × 0.54 for aspirin) and 0.14 (0.54 for statins × 0.26 
for aspirin), respectively.[6]
From the Vascular events In noncardiac Surgery patIents cOhort 
evaluatioN (VISION) Study data,[1] we determined the incidence 
of troponin-positive patients postoperatively (11.6%) and the 
expected mortality (1.9%). The expected incidence of cardiovascular 
complications associated with a troponin leak is shown in Fig. 1. In the 
VISION study, 45% of the deaths reported at 30 days were secondary 
to vascular causes. Vascular deaths were defined as deaths following a 
myocardial infarction, cardiac arrest, stroke, cardiac revascularisation 
procedure, pulmonary embolus or haemorrhage, or due to an unknown 
cause.[1] We estimated that 37.3% of patients who have a postoperative 
troponin leak[6] would have a clinical diagnosis of non-fatal myocardial 
infarction (3.96% of the VISION cohort). Furthermore, we expected 
73.4% of these complications to occur during the same admission for 
non-cardiac surgery, and the remaining 26.6% to occur after discharge 
but earlier than 30 days.[1]
Following initiation of statin and aspirin therapy in troponin-
positive patients, we estimated a 25% RRR for vascular mortality and 
non-fatal myocardial infarction. We did not consider any efficacy 
associated with statin and aspirin therapy in patients who sustained 
MINS and did not fulfil the criteria for a perioperative myocardial 
infarction, as currently there are no data on the efficacy of these 
therapies in MINS.
All costs used were averages based on private healthcare costs 
in South Africa (SA). The costs of troponin surveillance were 
based on costs from two private laboratories. We considered the 
cost of troponin surveillance for the first 3 postoperative days, i.e. 
postoperative days 1, 2 and 3, and the cost of 30 days of low-dose 
aspirin (80 - 100 mg daily) and statin (generic atorvastatin 40 mg 
daily) therapy in patients who were troponin-positive. Average drug 
costs for aspirin and atorvastatin were obtained from Discovery 
Health. We used a drug dispensing fee of R25.
The costs of all adverse events used in this analysis were based on 
average Discovery Health costs for the period January 2011 - June 
2011 for hospital admissions classified using Discovery’s Diagnosis 
Related Groups (DRG) system (Table 1). We used the following 
costs: (i) the average hospital cost of all fatal myocardial infarctions 
was used for the cost of a fatal myocardial infarction occurring after 
hospital discharge; and (ii) the average hospital cost of a non-fatal 
myocardial infarction (without complications) was used for the 
attributable cost of a non-fatal myocardial infarction occurring after 
hospital discharge. The cost of in-hospital myocardial infarctions was 
calculated as 155% of the DRG average cost of a non-cardiac surgery 
hospital admission, based on the work of Dimick et al.,[9] which 
showed that in-hospital cardiovascular complications following non-
cardiac surgery increased adjusted expenditure by 155% compared 
with a non-cardiac surgical admission with minor complications. We 
only adjusted for the cost of the in-hospital complication, and not 
for duration of stay, as cardiovascular complications associated with 
surgery have not been associated with an increase in the duration of 
hospital stay.[10]
Screening for troponins will also result in increased subsequent 
cardiovascular risk stratification of patients. We therefore included the 
cost of three in-hospital screening electrocardiograms (ECGs) in order 
to diagnose a perioperative myocardial infarction, and four specialist 
cardiologist consultations (two inpatient and two outpatient visits), a 
full lipid profile, and measurement of glycated haemoglobin (HbA1c) 
for the expected proportion of diabetics in the troponin-positive cohort 
(based on the VISION data)[1] for further risk stratification.
We constructed a monetary balance sheet in SA rands (ZAR) for 
the outcomes for a troponin surveillance group and a no-troponin 
surveillance group. All costs were calculated as the proportional 
cost per patient. For example, if 11.6% of patients were troponin-
positive, the cost of treating troponin-positive patients with statins 
and aspirin would be 0.116 × the cost of drug therapy. Similarly, the 
drug dispensing fee of R25 is therefore 0.116 × R25 as a proportional 
cost per individual.
We also considered the cost-effectiveness of postoperative 
troponin surveillance. A common definition of cost-effectiveness 
is whether the average per capita contribution to the national 
gross domestic product (GDP) over a year is greater than the cost 
of a particular secondary preventive intervention.[11] The average 
Table 1. Discovery Health’s Diagnosis Related Groups 
(DRGs) used in the study
DRG 53310: acute myocardial infarction without complications 
and comorbidities
DRG 53320: acute myocardial infarction with complications and 
comorbidities
DRG 53330: acute myocardial infarction with major 
complications and comorbidities
Non-cardiac surgery ≥45 years
Troponin leak 11.6%
Death 0.98%
Vascular death
0.47%
Non-vascular death
0.51%
Non-fatal troponin leak 10.62%
Perioperative
myocardial
infarction
3.96%
Myocardial injury
6.66%
Fig. 1. Expected cardiovascular complications following a troponin leak in 
patients ≥45 years of age undergoing non-cardiac surgery.
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per capita contribution to the GDP in SA 
is approximately R49 134.[12] By definition, 
therefore, a cost-effective intervention would 
cost less than R49 134 per event avoided.
Results
The average costs for troponin surveillance and 
the treatment of cardiovascular complications 
are shown in Table 2. The pharmaco economic 
analysis is shown in Table 3.
Discussion
This pharmacoeconomic analysis suggests that 
routine troponin surveillance in patients ≥45 
years of age undergoing non-cardiac surgery 
that requires a postoperative night in hospital 
is potentially cost-effective should statin and 
aspirin therapy decrease myocardial infarction 
and vascular mortality by 25%. Routine 
troponin surveillance was associated with a 
R32 410 increase in cost per event avoided, 
which remains cost-effective as it is less than 
the annual per capita contribution to the GDP.
The fact that routine troponin surveillance 
is potentially cost-effective is important, as 
over 65% of patients who have a postoperative 
myocardial infarction are asymptomatic,[3,4] 
and without troponin surveillance these cases 
will therefore be missed.
Although we have not considered any 
risk reduction associated with aspirin or 
statin therapy in patients with MINS in 
this pharmacoeconomic analysis, we would 
recommend that initiating these therapies 
after a diagnosis of MINS be considered in 
order to prevent a progression to myocardial 
infarction or vascular death. It is possible that 
these interventions may decrease subsequent 
cardiovascular morbidity in MINS patients 
who do not progress to myocardial infarction.
As a troponin leak is the largest contributor 
to 30-day postoperative mortality with a 
population-attributable risk of over 40%, 
when considered with preoperative and 
surgical risk factors[1] routine postoperative 
ECG surveillance would not be an acceptable 
substitute for troponin surveillance.
In conclusion, in the majority of cases the 
only way to identify patients who have had 
a myocardial infarction after non-cardiac 
surgery is to conduct routine postoperative 
troponin surveillance, and this is a potentially 
cost-effective intervention.
Statin and aspirin therapy
We did consider that introducing statin and 
aspirin therapy could increase drug-associated 
morbidity. The incidences of adverse events 
asso ciated with postoperative statin and 
aspirin therapy are based on two individual 
data meta-analyses of aspirin and statin 
therapy.[13,14] Statin therapy was not associated 
with significantly increased rhabdomyolysis 
in an individual patient data analysis of over 
90 000 patients from randomised controlled 
trials,[13] and no adverse effects are therefore 
expected for statin therapy.
Aspirin has been shown to increase major 
gastrointestinal bleeding (0.03% per year of 
therapy).[14] Theoretically this could lead to 
a 0.0025% (0.03%/12 months) increase in 
gastrointestinal bleeding within 30 days of 
surgery, or a number-needed-to-harm of 
40 000. A surgical meta-analysis suggests 
that the risk of postoperative bleeding 
is increased by a factor of 1.5 (median, 
interquartile range 1.0 - 2.5); however, only 
after transurethral prostatectomy (TURP) 
were there any deaths possibly attributable to 
bleeding.[15] The issue of increased bleeding 
risk following TURP has been challenged 
by subsequent authors, and a randomised 
controlled trial evaluating the effect of low-
dose acetylsalicylic acid on bleeding after 
TURP[16] showed that while postoperative 
blood loss was increased in patients receiving 
Table 2. Average costs used in the pharmacoeconomic analysis
Cost (ZAR)
Troponin surveillance, drug costs and cardiovascular risk stratification
Troponin surveillance (3 days) 732.00
Aspirin for 30 days 18.26
Atorvastatin for 30 days 95.60
ECG (three in hospital) 237.90
Full lipid profile 250.50
HbA1c 131.75
Cardiology consult 379.95
Cardiovascular complications
Non-fatal myocardial infarction 27 684.26
Fatal myocardial infarction 59 145.94
Additional cost of an in-hospital cardiovascular complication 70 363.80
ZAR = South African rands; ECG = electrocardiogram; HbA1c = glycated haemoglobin.
Table 3. The cost per patient (in ZAR) of troponin* or no troponin surveillance in 
SA non-cardiac surgical patients ≥45 years of age
Troponin 
surveillance 
No troponin 
surveillance
Direct and indirect costs of troponin surveillance and therapy (A)
Cost of troponin surveillance for 3 days 732 0
Cost of statin and aspirin therapy for 30 days 13.21 0
Drug dispensing fee 2.9 0
Costs of perioperative cardiovascular complications (B)
Cost of fatal myocardial infarction 581.15 660.32
 Cost of non-fatal myocardial infarction without 
complications
1 988.76 2 336.84
Total cost per patient
(C = A + B)
3 318.02 (C1) 2 997.16 (C2)
Total incremental cost for surveillance and therapy
(D = C1 – C2)
320.86
Absolute risk reduction 0.99
NNT to prevent 1 event 101
Total incremental cost
(E = D × NNT)
32 409.80
Cost-effectiveness in SA patients
(F = E – R49 134)[11]
–16 724.20
SA = South African; NNT = number-needed-to-treat; RRR = relative risk reduction.
*Scenario based on a 25% RRR in vascular mortality only and non-fatal myocardial infarction only.
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aspirin therapy, there was no significant difference in operative 
blood loss, median time to catheter removal, length of hospital 
stay or the incidence of readmission to hospital due to secondary 
haemorrhage. As a result, the meta-analysis by Burger et al.[15] 
makes no recommendations regarding perioperative aspirin use, and 
suggests that a controlled trial of surgical patients is needed.
The recently published PeriOperative Ischemic Evaluation-2 
(POISE-2) trial[17] did, however, show that aspirin given during surgery 
increased perioperative bleeding, and this risk remained until the 8th 
postoperative day. What is currently unclear is whether the initiation 
of aspirin therapy following a troponin leak in the postoperative 
period carries a similar bleeding risk to that in the POISE-2 trial. We 
would encourage vigilance once aspirin is initiated in the postoperative 
period, until such time as there are data to inform this issue.
We would still recommend initiation of aspirin therapy in 
patients who are troponin-positive postoperatively, as in secondary 
prevention trials aspirin decreases serious vascular events (number-
needed-to-treat (NNT) 67) and coronary events (NNT 100),[14] and 
this is consistent with the observational data from the POISE trial 
in surgical patients.[3] Troponin screening in an at-risk population 
and the initiation of aspirin therapy in those with increased troponin 
levels is therefore likely to be a cost-effective intervention.
There are a number of compelling reasons to believe that this 
pharmacoeconomic analysis may be conservative, and the benefits 
associated with routine troponin surveillance and statin and aspirin 
therapy may be larger than what is presented here.
Firstly, it is possible that routine troponin surveillance may also 
decrease subsequent morbidity and mortality associated with MINS 
through institution of appropriate treatment of underlying coronary 
artery disease, especially as MINS is associated with increased long-
term cardiovascular morbidity.[5] We would expect further benefit in 
patients with MINS, as these patients have been shown to have an 
increased risk of non-fatal cardiac arrest and subsequent coronary 
revascularisation.[6] It has been shown in a meta-analysis of over 
170  000 patients that the addition of statin therapy significantly 
decreases subsequent coronary revascularisation,[18] so there may be 
additional cost-saving benefits associated with treating postoperative 
myocardial injury that have not been calculated here.
Secondly, it is likely that statin and aspirin therapy may also 
decrease non-vascular mortality in addition to vascular mortality. A 
postoperative troponin leak is independently predictive of all-cause 
mortality, and this may be because an early postoperative myocardial 
injury often precedes further non-cardiac complications, aggravating 
their severity, which results in death.[1] A postoperative troponin 
leak may therefore also be an initiating event in a non-vascular 
postoperative death. Importantly, and consistent with this conclusion, 
is that statins and aspirin were associated with a reduction in all-
cause mortality in the POISE study.[3] It is therefore possible that if 
statin and aspirin administration decreased all-cause mortality and 
all myocardial injury after non-cardiac surgery by 25%, there would 
be an overall cost saving with aspirin and statin therapy following 
routine troponin surveillance for non-cardiac surgery.
Thirdly, both statin and aspirin in secondary prevention trials 
have also decreased subsequent fatal and non-fatal stroke.[14,18] This 
pharmacoeconomic analysis only considered fatal stroke, which is 
part of the definition of vascular mortality.[1]
It is also possible that the costs we have used in this pharmaco-
economic analysis are conservative. Davenport et al.[10] have 
suggested that cardiovascular complications associated with surgery 
increase costs by 459% as opposed to the 155% used in this 
analysis, which would result in a cost saving associated with routine 
troponin surveillance of R16 700 per event avoided in our analysis. 
Furthermore, the predicted costs of treating myocardial infarctions in 
2011 across all medical aid providers was R78 869,[19] which is higher 
than the Discovery Health costs for the same period used in this 
analysis. If the average cost of all medical aid providers was used in 
our model, there would have been an absolute cost saving per event 
avoided. Both these possible scenarios change this intervention from 
a cost-effective intervention to a cost-saving intervention.
An outcome that may change the cost-effectiveness of this 
pharmacoeconomic analysis is out-of-hospital sudden death, which 
is associated with no additional cost. When we considered this 
scenario for all out-of-hospital deaths in the analysis, routine 
troponin screening remained cost-effective.
Finally, it is important that the finding of a postoperative troponin 
leak does not lead to an unnecessary increase in expenditure associated 
with subsequent inappropriate coronary angiography investigation. 
We would advise against routine coronary angiography if the patient 
does not fulfil current accepted indications for this procedure. This is 
because significant differences exist between spontaneous (medical) 
myocardial infarctions and myocardial infarction following surgery.[20] 
The postoperative patient is exposed to an environment associated 
with haemodynamic instability, procoagulation, sympathetic 
stress and potential bleeding and hypoxia,[21] and as such the 
pathophysiology of the perioperative myocardial infarction is likely 
to be different to the myocardial infarction characteristic of medical 
patients.[22] These factors may partly explain the predominance of 
ST-segment depression with surgical myocardial infarctions.[3,23] We 
would recommend a conservative approach to coronary angiography 
in patients with a postoperative troponin leak, until such time as the 
coronary computed tomography angiography data from the VISION 
study are published.[24] Furthermore, as there are no prospective 
studies on managing perioperative myocardial infarctions and MINS, 
the current recommendations for coronary angiography in these 
patients include very specific scenarios that probably occur in a very 
small group of patients (in the region of 2 - 3% of patients who have 
a documented myocardial infarction).[25,26]
Finally, although our pharmacoeconomic analysis was conducted for 
troponin surveillance of all non-cardiac surgical patients ≥45 years of 
age requiring an overnight hospital stay, the recently published MINS 
study showed that low-risk surgery was independently protective for 
the development of MINS (hazard ratio 0.72; 95% CI 0.55 - 0.99).[7] We 
would therefore not recommend routine troponin surveillance for low-
risk surgical procedures as defined in the VISION study.
Study limitations
There are limitations that may affect the accuracy of this pharmaco-
economic analysis. The analysis was conducted without consideration of 
potential postoperative troponin surveillance that is already conducted 
following some high-risk surgical procedures. This would not change 
the outcome of this analysis, as we therefore overestimated the cost of 
this suggested change to routine troponin surveillance. However, the 
importance of our analysis is that it suggests that extending the scope 
of troponin surveillance is potentially cost-effective, provided effective 
therapy is immediately provided when a troponin leak is detected.
Furthermore, there are no data indicating that interventions for MINS 
decrease subsequent major adverse cardiac events in low-risk patients. 
We therefore cannot include this analysis in the pharmacoeconomic 
analysis, although it is an area that may be associated with a large public 
health benefit, should efficacy be shown in these patients. This is an 
area of perioperative medicine that requires urgent investigation. Based 
on the increased mortality and cardiovascular morbidity,[5,7] we would 
recommend considering these patients for subsequent secondary 
prevention for coronary artery disease.
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Conclusion
This pharmacoeconomic analysis suggests that routine postoperative 
troponin surveillance is a potentially cost-effective intervention in all 
patients ≥45 years of age undergoing inpatient non-cardiac surgery.
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